Luteinizing hormone-releasing hormone antagonists. - Wikidata - awgldk - TriplyDB

Luteinizing hormone-releasing hormone antagonists.

Luteinizing hormone-releasing hormone antagonists.

http://www.wikidata.org/entity/Q37638747

about

Investigation on chemotactic drug targeting (chemotaxis and adhesion) inducer effect of GnRH-III derivatives in Tetrahymena and human leukemia cell line.Recent Development of Non-Peptide GnRH Antagonists.

P2860

Q39233095-D6974D07-E7E0-4046-A36D-1079A697E7F0 Q47323557-4D93CBB2-A328-4C4C-908D-55E6B8F5626D

P2860

Luteinizing hormone-releasing hormone antagonists.

http://www.wikidata.org/entity/Q37638747

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Luteinizing hormone-releasing hormone antagonists.

@en

Luteinizing hormone-releasing hormone antagonists.

@nl

type

label

Luteinizing hormone-releasing hormone antagonists.

@en

Luteinizing hormone-releasing hormone antagonists.

@nl

prefLabel

Luteinizing hormone-releasing hormone antagonists.

@en

Luteinizing hormone-releasing hormone antagonists.

@nl

P1433

Q37638747-012F31EE-A3C4-4341-9367-57FB61E1CD53

P1476

Q37638747-A9926827-2A6B-439C-AF4B-28928F43AF5E

P2093

Q37638747-10826D48-2D2D-4210-A436-190E69F545F1

Q37638747-22B26BA6-4A50-4821-AB7B-783F0D385FED

P2860

Q37638747-054A2FF4-961C-440C-BDD3-4574E7C304D1

Q37638747-0F5CC082-ABF8-4591-8713-2E3D02D15BFD

Q37638747-1400CC16-DF25-40E8-BFDE-752CE0A18092

Q37638747-143E3595-9F01-49B4-83AA-4AD2D8EF1934

Q37638747-1D6F9687-2745-4AE2-AD4F-2A76FF85BE4A

Q37638747-2B81FD3B-FA25-4804-A1A1-5631657E2D87

Q37638747-2DD29C76-7317-43D9-9E68-DB6C26F9EFEF

Q37638747-31857446-925A-4A29-9FEC-845CCD5ABA94

Q37638747-34A66D60-4737-47E4-8AF1-64D6FBE07DC5

Q37638747-4477ED83-33B2-421A-9BA6-3D53AD726A33

P304

Q37638747-3876CF90-61D3-4B4A-B046-7634E86E6418

P31

Q37638747-10F6881B-9B50-4FBF-86BC-0B3132D38622

P356

Q37638747-6BCB1AB0-3947-4B9F-9110-94ADFF3D569C

P407

Q37638747-B5E98F12-A988-43CB-B190-10063A6D465C

P433

Q37638747-F0D78F7F-FA91-49A9-A169-F92E75007F3B

P478

Q37638747-35B39BEE-7DAF-47CF-85AE-DEDB766AE786

P577

Q37638747-98866935-9458-42EE-AEBD-9DEA52FF0508

P5875

Q37638747-17CA226D-9CAA-48AC-98DD-395D87F3B7DB

P698

Q37638747-319ED38A-9499-40EA-B431-F5FF7B253E28

P356

13543770903410237

P1433

Expert Opinion on Therapeutic Patents

P1476

Luteinizing hormone-releasing hormone antagonists.

@en

P2093

Gábor Mezo

http://www.w3.org/2001/XMLSchema#string

Marilena Manea

http://www.w3.org/2001/XMLSchema#string

P2860

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

GnRH analogues--agonists and antagonists

GnRHs and GnRH receptors

Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists.

Development of GnRH antagonists for prostate cancer: new approaches to treatment.

Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor.

The LHRH antagonist cetrorelix: a review.

Biology of the gonadotropin-releasing hormone system in gynecological cancers.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

The use of GnRH antagonists in ovarian stimulation.

P304

1771-1785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543770903410237

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40032415

http://www.w3.org/2001/XMLSchema#string

P698

19939192

http://www.w3.org/2001/XMLSchema#string